The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: Results from a retrospective study

Quality of Life Research

Volumn 7, Issue 5, 1998, Pages 373-386

  Damiano, A M ^a,d   Pastores, G M ^b   Ware Jr , J E ^c  

^a Outcomes Studies Group   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d Covance Hlth Econ Outcome Serv I ^*  (United States)

Author keywords

Cross sectional; Gaucher's disease; Glucocerebrosidase; Health related quality of life; Retrospective recall; SF 36 Health Survey

Indexed keywords

GLUCOSYLCERAMIDASE;

ADOLESCENT; ADULT; ARTICLE; CHRONIC DISEASE; ENZYME REPLACEMENT; FEMALE; FUNCTIONAL ASSESSMENT; GAUCHER DISEASE; HEALTH SURVEY; HUMAN; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOMES RESEARCH; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INTERVIEWS; LOGISTIC MODELS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 0031877439     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008814105603     Document Type: Article

References (25)

1. Grawbowski GA. Gaucher disease: enzymology, genetics and treatment. In: Harris H, Hirschhorn K, eds. Advances in Human Genetics. New York: Plenum Press, 1993: 377-441.
2. Beutler E. Gaucher's disease. N Engl J Med 1991; 325: 1354-1360.
3. NIH Technology Assessment Panel on Gaucher Disease. Gaucher Disease: current issues in diagnosis and treatment. J Am Med Assoc 1996; 275: 548-553.
4. Thanopoulos BD, Frimas CA, Mantagos P, Beratis NG. Gaucher disease: treatment of hypersplenism with splenic embolization. Acta Paediatr Scand 1987; 76: 1003-1007.
5. Cohen IJ, Katz K, Freud E, Zer M, Zaizov R. Long-term follow-up of partial splenectomy in Gaucher's disease. Am J Surg 1992; 164: 345-347.
6. Grecula MJ, Grigoris P, Amstutz HC. The surgical management of femoral head osteonecrosis in Gaucher disease. Gaucher Clin Perspect 1994; 2: 1-4.
7. Yosipovitch Z, Katz K. Bone crisis in Gaucher disease - an update. Israel J Med Sci 1990; 26: 593-595.
8. Katz K, Cohen IJ, Ziv W et al. Fractures in children who have Gaucher disease. J Bone Joint Surg 1987; 69-A: 1361-1370.
9. Zimran A, Hollak CEM, Abrahamor A, VanDers MHJ, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993; 82: 1107-1109.
10. Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage targeted glucocerebrosidase. Pediatrics 1995; 96: 629-637.
11. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470.
12. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse events in 33 patients treated for 6 to 24 months. Blood 1993; 82: 408-416.
13. Whittington R, Goa KL. Alglucerase: a pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease. PharmacoEconomics 1995; 7: 63-90.
14. Verderese CL, Graham OC, Holder-McShane CA, Harnett NE, Barton NW. Gaucher's disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nursing 1993; 25: 296-301.
15. Ware JE, Brook RH, Davies-Avery A et al. Conceptualization and Measurement of Health for Adults in the Health Insurance Study; Volume 1, Model of Health and Methodology. Santa Monica: The Rand Corporation, 1980.
16. Ware JE, Brook RH, Rogers WH et al. Comparison of health outcomes at a health maintenance organization with those of the fee-for-service care. Lancet 1986; 1017-1021.
17. Zimran A, Elstein D, Kannai R et al. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 1994; 97: 3-11.
18. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
19. McHorney CA, Ware JE, Raczek AE. The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263.
20. McHorney CA, Ware JE, Lu JFR, Sherbourne LD. The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
21. Stewart AL, Ware JE, eds. Measuring Function and Well-being: The Medical Outcomes Study Approach. Durham: Duke University Press, 1992.
22. Ware JE, Bayliss MS, Rogers WH, Kosinski M, Tarlov AR. Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems: results from the Medical Outcomes Study. J Am Med Assoc 1996; 276: 1039-1047.
23. Ware JE, Kosinski MA, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, New England Medical Center, 1994.
24. Ware JE, Kosinski MA, Bayliss MA, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33: AS264-AS279.
25. McHorney CA, Kosinski M, Ware JE. Comparisons of the costs and quality of norms for the SF-36 Health Survey collected by mail versus telephone interview: results from a national survey. Med Care 1994; 32: 551-567.